Abivax presented further analyses from its pivotal Phase 3 trial of obefazimod, its lead drug candidate for ulcerative colitis. The pooled data from nearly 1,300 patients reinforce the therapeutic benefit observed in prior readouts, supporting obefazimod's differentiated mechanism and clinical efficacy. Following its initial positive Phase 3 results, the drug has positioned Abivax as a rising player in inflammatory bowel disease therapeutics. The company continues to advance commercialization efforts with strong market interest.